Recce Pharmaceuticals
Recce Pharmaceuticals Ltd is an Australian pharmaceutical company focused on developing a new class of synthetic anti-infectives to combat antibiotic-resistant superbugs. Their lead candidate, RECCE® 327, has received Qualified Infectious Disease Product (QIDP) designation from the FDA, offering potential market exclusivity. The company aims to provide effective treatments against a broad range of bacteria and viral indications.
Short position
Recce Pharmaceuticals (ASX:RCE) has 0.00% of its shares on issue reported as short positions as of 5 Oct 2026, or about 4,267 shares. Over the past 30 days that figure has been broadly flat, and over 90 days it has been broadly flat. Its highest recorded short interest was 0.37% in August 2021. RCE is classified in the Pharmaceuticals, Biotechnology & Life Sciences industry. All figures come from official ASIC short position reports, published with a four trading-day (T+4) delay.
Price & short interest
Toggle series, zoom, and compare · ASIC daily, T+4RCE community
Research Threads
Bull, bear, catalyst, and news-reaction posts tied directly to RCE.
Start the first RCE research thread
Anchor the conversation with a thesis, a catalyst, or a question worth debating.